• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

萨尔维诺灵B甲氧基甲基醚

Salvinorin B meth-oxy-methyl ether.

作者信息

Munro Thomas A, Ho Douglas M, Cohen Bruce M

机构信息

McLean Hospital, Belmont, MA, USA ; Harvard Medical School, Department of Psychiatry, Boston, MA, USA.

出版信息

Acta Crystallogr Sect E Struct Rep Online. 2012 Nov 1;68(Pt 11):o3225-6. doi: 10.1107/S1600536812043449. Epub 2012 Oct 27.

DOI:10.1107/S1600536812043449
PMID:23284529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3515309/
Abstract

The title compound [MOM-SalB; systematic name: methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(3-fur-yl)-9-meth-oxy-meth-oxy-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octa-hydro-1H-benzo[f]isochromene-7-carboxyl-ate], C(23)H(30)O(8), is a deriv-ative of the κ-opioid salvinorin A with enhanced potency, selectivity, and duration of action. Superimposition of their crystal structures reveals, surprisingly, that the terminal C and O atoms of the MOM group overlap with the corresponding atoms in salvinorin A, which are separated by an additional bond. This counter-intuitive isosterism is possible because the MOM ether adopts the 'classic anomeric' conformation (gauche-gauche), tracing a helix around the planar acetate of salvinorin A. This overlap is not seen in the recently reported structure of the tetra-hydro-pyranyl ether, which is less potent. The classic anomeric conformation is strongly favoured in alk-oxy-methyl ethers, but not in substituted acetals, which may contribute to their reduced potency. This structure may prove useful in evaluating models of the activated κ-opioid receptor.

摘要

标题化合物[MOM-SalB;系统名称:甲基(2S,4aR,6aR,7R,9S,10aS,10bR)-2-(3-呋喃基)-9-甲氧基甲氧基-6a,10b-二甲基-4,10-二氧代-2,4a,5,6,7,8,9,10a-八氢-1H-苯并[f]异苯并二氢吡喃-7-羧酸酯],C(23)H(30)O(8),是κ-阿片样物质萨尔维诺林A的衍生物,具有增强的效力、选择性和作用持续时间。令人惊讶的是,它们晶体结构的叠加显示,MOM基团的末端C和O原子与萨尔维诺林A中的相应原子重叠,而这些原子被一个额外的键隔开。这种违反直觉的等电子体现象是可能的,因为MOM醚采用了“经典异头物”构象(gauche-gauche),围绕萨尔维诺林A的平面乙酸酯形成一个螺旋。在最近报道的效力较低的四氢吡喃基醚结构中没有看到这种重叠。经典异头物构象在烷氧基甲基醚中强烈有利,但在取代缩醛中则不然,这可能导致它们效力降低。该结构可能有助于评估活化的κ-阿片样物质受体模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/e09bba3919e4/e-68-o3225-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/ea9cc67a14f3/e-68-o3225-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/83c8a0e8b888/e-68-o3225-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/7bd9a5d6870f/e-68-o3225-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/e09bba3919e4/e-68-o3225-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/ea9cc67a14f3/e-68-o3225-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/83c8a0e8b888/e-68-o3225-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/7bd9a5d6870f/e-68-o3225-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/3515309/e09bba3919e4/e-68-o3225-fig4.jpg

相似文献

1
Salvinorin B meth-oxy-methyl ether.萨尔维诺灵B甲氧基甲基醚
Acta Crystallogr Sect E Struct Rep Online. 2012 Nov 1;68(Pt 11):o3225-6. doi: 10.1107/S1600536812043449. Epub 2012 Oct 27.
2
(2S,4aR,6aR,7R,9S,10aS,10bR)-7-Carb-oxy-2-(3-fur-yl)-6a,10b-dimethyl-4,10-dioxoperhydro-benzo[f]isochromen-9-yl acetate.(2S,4aR,6aR,7R,9S,10aS,10bR)-7-羧基-2-(3-呋喃基)-6a,10b-二甲基-4,10-二氧代全氢苯并[f]异色烯-9-基乙酸酯
Acta Crystallogr Sect E Struct Rep Online. 2009 Feb 6;65(Pt 3):o471-2. doi: 10.1107/S1600536809002074.
3
Salvinorin A: allosteric interactions at the mu-opioid receptor.Salvinorin A:μ-阿片受体上的变构相互作用。
J Pharmacol Exp Ther. 2007 Feb;320(2):801-10. doi: 10.1124/jpet.106.113167. Epub 2006 Oct 23.
4
Unusual hemiacetal structure derived from Salvinorin A.源自鼠尾草酚A的不寻常半缩醛结构。
Acta Crystallogr Sect E Struct Rep Online. 2008 Jun 28;64(Pt 7):o1370-1. doi: 10.1107/S160053680800144X.
5
Bioisosteric modification of salvinorin A, a potent and selective kappa-opioid receptor agonist.具有强效和选择性的κ-阿片受体激动剂——萨尔维诺林A的生物电子等排体修饰
Arzneimittelforschung. 2006;56(4):269-75. doi: 10.1055/s-0031-1296720.
6
Xyloccensin L.木通辛素L
Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 24;66(Pt 8):o2111-2. doi: 10.1107/S1600536810028527.
7
Swietenolide diacetate from the seeds of Swietenia macrophylla.来自大叶桃花心木种子的二乙酸斯维特诺内酯
Acta Crystallogr Sect E Struct Rep Online. 2010 May 22;66(Pt 6):o1396. doi: 10.1107/S1600536810017733.
8
Crystal structure of (E)-1-(4-meth-oxy-phen-yl)ethanone O-de-hydro-abietyloxime.(E)-1-(4-甲氧基苯基)乙酮O-去氢枞酰肟的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Aug 1;70(Pt 9):o948. doi: 10.1107/S1600536814016882. eCollection 2014 Sep 1.
9
Crystal structure of (E)-13-{4-[(Z)-2-cyano-2-(3,4,5-tri-meth-oxy-phen-yl)ethen-yl]phen-yl}parthenolide methanol hemisolvate.(E)-13-{4-[(Z)-2-氰基-2-(3,4,5-三甲氧基苯基)乙烯基]苯基}小白菊内酯甲醇半溶剂化物的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Sep 6;70(Pt 10):o1092-3. doi: 10.1107/S1600536814019333. eCollection 2014 Oct 1.
10
A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat kappa-opioid receptor in human embryonic kidney 293 cells.一组特定的阿片样物质配体通过促进大鼠κ-阿片受体在人胚肾293细胞中的成熟和稳定性来诱导上调。
J Pharmacol Exp Ther. 2007 Nov;323(2):614-25. doi: 10.1124/jpet.107.125500. Epub 2007 Aug 24.

引用本文的文献

1
Emerging paradigms for target discovery of traditional medicines: A genome-wide pan-GPCR perspective.传统药物靶点发现的新兴模式:全基因组泛G蛋白偶联受体视角
Innovation (Camb). 2025 Jan 17;6(3):100774. doi: 10.1016/j.xinn.2024.100774. eCollection 2025 Mar 3.
2
Studies toward bivalent κ opioids derived from salvinorin A: heteromethylation of the furan ring reduces affinity.源自 Salvinorin A 的双价 κ 阿片受体激动剂的研究:呋喃环的杂甲基化降低了亲和力。
Beilstein J Org Chem. 2013 Dec 20;9:2916-24. doi: 10.3762/bjoc.9.328.

本文引用的文献

1
Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.源自致幻天然产物Salvinorin A的潜在药物滥用治疗方法。
Medchemcomm. 2011 Dec;2(12):1217-1222. doi: 10.1039/C1MD00192B.
2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.12-表萨尔维尼醇 A 及其类似物在 κ 阿片受体上的差异信号转导特性。
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1023-6. doi: 10.1016/j.bmcl.2011.11.128. Epub 2011 Dec 7.
3
Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A.
Salvinorin B衍生物,EOM-Sal B和MOM-Sal B,在经过训练以区分Salvinorin A的雄性Sprague-Dawley大鼠中产生刺激泛化。
Behav Pharmacol. 2011 Sep;22(5-6):450-7. doi: 10.1097/FBP.0b013e328349fc1b.
4
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.天然 κ-阿片样物质致幻剂藜芦醛甲醚的神经药理学。
Pharmacol Rev. 2011 Jun;63(2):316-47. doi: 10.1124/pr.110.003244. Epub 2011 Mar 28.
5
Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.萨尔维诺灵A及其衍生物:免受代谢作用并不会延长其在短期全脑的停留时间。
Neuropharmacology. 2009 Sep;57(4):386-91. doi: 10.1016/j.neuropharm.2009.06.044. Epub 2009 Jul 8.
6
Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.大鼠中鼠尾草酸A及其衍生物对U69,593和U50,488的辨别刺激效应比较。
Psychopharmacology (Berl). 2009 Apr;203(2):203-11. doi: 10.1007/s00213-008-1458-3. Epub 2009 Jan 20.
7
Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis.源自晶体结构数据的小分子构象偏好。一项聚焦于药物化学的分析。
J Chem Inf Model. 2008 Jan;48(1):1-24. doi: 10.1021/ci7002494. Epub 2008 Jan 10.
8
A short history of SHELX.SHELX简史。
Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22. doi: 10.1107/S0108767307043930. Epub 2007 Dec 21.
9
2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A.2-甲氧基甲基-萨尔维诺林B是一种强效κ阿片受体激动剂,在体内的作用持续时间比萨尔维诺林A更长。
J Pharmacol Exp Ther. 2008 Mar;324(3):1073-83. doi: 10.1124/jpet.107.132142. Epub 2007 Dec 18.
10
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.标准保护基团可生成强效且具选择性的κ阿片样物质:萨尔维诺林B烷氧基甲基醚。
Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. doi: 10.1016/j.bmc.2007.10.067. Epub 2007 Oct 24.